Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

Cancer Cell

Volumn 29, Issue 4, 2016, Pages 563-573

  Wei, Wei ^a,b,c   Shin, Young Shik ^a,c   Xue, Min ^a   Matsutani, Tomoo ^d   Masui, Kenta ^d   Yang, Huijun ^d   Ikegami, Shiro ^d   Gu, Yuchao ^d   Herrmann, Ken ^c   Johnson, Dazy ^c   Ding, Xiangming ^c   Hwang, Kiwook ^a   Kim, Jungwoo ^a   Zhou, Jian ^c   Su, Yapeng ^a   Li, Xinmin ^c   Bonetti, Bruno ^e   Chopra, Rajesh ^f   James, C David ^g   Cavenee, Webster K ^d   Cloughesy, Timothy F ^c   Mischel, Paul S ^d   Heath, James R ^a,c   Gini, Beatrice ^d   more..

^a California Institute of Technology   (United States)

^b California Institute of Technology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF VERONA   (Italy)

^f CELGENE CORPORATION   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CC 214 2; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TRAMETINIB; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; ANTINEOPLASTIC AGENT; CC214-2; EGFR PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; NITRILE; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TUMOR PROTEIN;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CASE REPORT; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; GLUCOSE TRANSPORT; HETEROZYGOSITY LOSS; HUMAN; IN VITRO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; TUMOR VOLUME; TUMOR XENOGRAFT; ADAPTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETIC SELECTION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROTO ONCOGENE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BUTADIENES; DASATINIB; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENES, ERBB-1; GLIOBLASTOMA; HUMANS; MICE; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MULTIPROTEIN COMPLEXES; MUTATION; NEOPLASM PROTEINS; NITRILES; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTEOMICS; PYRAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SELECTION, GENETIC; SIGNAL TRANSDUCTION; SINGLE-CELL ANALYSIS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962725073     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.012     Document Type: Article

References (43)

1. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30:679-691.
2. Bailey R.C., Kwong G.A., Radu C.G., Witte O.N., Heath J.R. DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins. J. Am. Chem. Soc. 2007, 129:1959-1967.
3. Bergers C., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
4. Bozic I., Reiter J.G., Allen B., Antal T., Chatterjee K., Shah P., Moon Y.S., Yaqubie A., Nelly N., Le D.T., et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013, 2:e00747.
5. Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., et al. The somatic genetic landscape of glioblastoma. Cell 2013, 155:462-477.
6. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
7. Chin L., Meyerson M., Aldape K., Bigner D., Mikkelsen T., VandenBerg S., Kahn A., Penny R., Ferguson M.L., Gerhard D.S., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
8. Cloughesy T.F., Mischel P.S. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target?. Clin. Cancer Res. 2011, 17:6-11.
9. Cloughesy T.F., Mischel P.S., Omuro A.M.P., Prados M., Wen P.Y., Wu B., Rockich K., Xu Y., Lager J.J., Mellinghoff I.K. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): an Ivy Foundation Early-phase Clinical Trials Consortium Study. J. Clin. Oncol. 2013, 31. (suppl; abstr 2012).
10. Cope C.L., Gilley R., Balmanno K., Sale M.J., Howarth K.D., Hampson M., Smith P.D., Guichard S.M., Cook S.J. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J. Cell Sci. 2014, 127:788-800.
11. Dooraghi A.A., Vu N.T., Silverman R.W., Farrell R., Shah K.S., Wang J., Heath J.R., Chatziioannou A.F. Betabox: a beta particle imaging system based on a position sensitive avalanche photodiode. Phys. Med. Biol. 2013, 58:3739-3753.
12. Elkabets M., Vora S., Juric D., Morse N., Mino-Kenudson M., Muranen T., Tao J., Campos A.B., Rodon J., Ibrahim Y.H., et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 2013, 5:196ra199.
13. Fenton T.R., Nathanson D., Ponte de Albuquerque C., Kuga D., Iwanami A., Dang J., Yang H., Tanaka K., Oba-Shinjo S.M., Uno M., et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc. Natl. Acad. Sci. USA 2012, 109:14164-14169.
14. Gini B., Zanca C., Guo D., Matsutani T., Masui K., Ikegami S., Yang H., Nathanson D., Villa G.R., Shackelford D., et al. The mTOR kinase inhibitors CC214-1 and CC214-2 preferentially block the growth of EGFRvIII-activated glioblastomas. Clin. Cancer Res. 2013, 19:5722-5732.
15. Heath J.R., Ribas A., Mischel P.S. Single-cell analysis tools for drug discovery and development. Nat. Rev. Drug Discov. 2016, 15:204-216.
16. Hu Y., Lu H., Zhang J., Chen J., Chai Z., Zhang J. Essential role of AKT in tumor cells addicted to FGFR. Anticancer Drugs 2014, 25:183-188.
17. Irish J.M., Hovland R., Krutzik P.O., Perez O.D., Bruserud O., Gjertsen B.T., Nolan G.P. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-228.
18. Iyer G., Hanrahan A.J., Milowsky M.I., Al-Ahmadie H., Scott S.N., Janakiraman M., Pirun M., Sander C., Socci N.D., Ostrovnaya I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338:221.
19. Janes K.A., Albeck J.G., Gaudet S., Sorger P.K., Lauffenburger D.A., Yaffe M.B. Systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005, 310:1646-1653.
20. Kalisky T., Blainey P., Quake S.R. Genomic analysis at the single-cell level. Annu. Rev. Genet. 2011, 45:431-445.
21. Krakstad C., Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol. Cancer Ther. 2010, 9:135.
22. Lee M.J., Ye A.S., Gardino A.K., Heijink A.M., Sorger P.K., MacBeath G., Yaffe M.B. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 148:780-794.
23. Lu K.V., Zhu S., Cvrljevic A., Huang T.T., Sarkaria S., Ahkavan D., Dang J., Dinca E.B., Plaisier S.B., Oderberg I., et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009, 69:6889-6898.
24. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 2012, 12:323-334.
25. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353:2012-2024.
26. Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 2011, 36:320-328.
27. Mortensen D.S., Sapienza J., Lee B.G.S., Perrin-Ninkovic S.M., Harris R., Shevlin G., Parnes J.S., Whitefield B., Hickman M., Khambatta G., et al. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorg. Med. Chem. Lett. 2013, 23:1588-1591.
28. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
29. Nathanson D., Gini B., Mottahedeh J., Visnyei K., Koga T., Gomez G., Eskin A., Hwang K., Wang J., Masui K., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2014, 343:72-76.
30. Pisco A.O., Brock A., Zhou J., Moor A., Mojtahedi M., Jackson D., Huang S. Non-Darwinian dynamics in therapy-induced cancer drug resistance. Nat. Commun. 2013, 4:2467.
31. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
32. Rodrik-Outmezguine V.S., Yao Z., Mukherjee R., Cai L., Barratt D., Ward R., Klinowska T., De Stanchina E., Berger M., Baselga J., Rosen N. Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein [abstract]. Cancer Res. 2014, 74(19 Suppl):1726.
33. Sarkaria J.N., Yang L., Grogan P.T., Kitange G.J., Carlson B.L., Schroeder M.A., Galanis E., Giannini C., Wu W., Dinca E.B., James C.D. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 2007, 6:1167-1174.
34. Schonberg D.L., Lubelski D., Miller T.E., Rich J.N. Brain tumor stem cells: molecular characteristics and their impact on therapy. Mol. Aspects Med. 2014, 39:82-101.
35. Shi Q., Qin L., Fan R., Wei W., Guo D., Shin Y.S., Hood L., Mischel P.S., Heath J.R. Single cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc. Natl. Acad. Sci. USA 2012, 109:419-425.
36. Sunayama J., Matsuda K.I., Sato A., Tachibana K., Suzuki K., Narita Y., Shibui S., Sakurada K., Kayama T., Tomiyama A., Kitanaka C. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010, 28:1930-1939.
37. Wacker S.A., Houghtaling B.R., Elemento O., Kapoor T.M. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat. Chem. Biol. 2012, 8:235-237.
38. Wagle N., Grabiner B.C., Van Allen E.M., Amin-Mansour A., Taylor-Weiner A., Rosenberg M., Gray N., Barletta J.A., Guo Y., Swanson S.J., et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N. Engl. J. Med. 2014, 371:1426-1433.
39. Wang J., Hwang K., Brass D., Dooraghi A., Nathanson D., Campbell D.O., Gu J., Sandberg T., Mischel P.S., Radu C.G., et al. Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system. J. Nucl. Med. 2013, 54:1820-1824.
40. Ward J.H. Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 1963, 58:236-244.
41. Wei W., Shi Q., Remacle F., Qin L., Shackelford D., Shin Y.S., Mischel P.S., Levine R.D., Heath J.R. Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proc. Natl. Acad. Sci. USA 2013, 110:E1352-E1360.
42. Wu A.R., Neff N.F., Kalisky T., Dalerba P., Treutlein B., Rothenberg M.E., Mburu F.M., Mantalas G.L., Sim S., Clarke M.F., Quake S.R. Quantitative assessment of single-cell RNA-sequencing methods. Nat. Methods 2014, 11:41-46.
43. Zhang H., Cicchetti G., Onda H., Koon H.B., Asrican K., Bajraszewski N., Vazquez F., Carpenter C.L., Kwiatkowski D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 2003, 112:1223-1233.